Teva Pharmaceutical (TEVA) Tops Q3 EPS by 3c; Guides In-Line
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Join SI Premium – FREE
Teva Pharmaceutical (NASDAQ: TEVA) reported Q3 EPS of $1.28, $0.03 better than the analyst estimate of $1.25. Revenue for the quarter rose 14% to $5 billion versus the consensus estimate of $5.08 billion.
Teva Pharmaceutical sees FY2012 EPS of $5.32-5.38, versus prior guidance of $5.30-5.40 and the consensus of $5.36. Teva Pharmaceutical sees FY2012 revenue of $20.1-20.7 billion, versus the consensus of $20.47 billion.
For earnings history and earnings-related data on Teva Pharmaceutical (TEVA) click here.
Teva Pharmaceutical sees FY2012 EPS of $5.32-5.38, versus prior guidance of $5.30-5.40 and the consensus of $5.36. Teva Pharmaceutical sees FY2012 revenue of $20.1-20.7 billion, versus the consensus of $20.47 billion.
For earnings history and earnings-related data on Teva Pharmaceutical (TEVA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
- Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
